

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

1. **(Currently Amended)** A method for determining whether ~~an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs~~ paclitaxel and ~~cisplatin derivatives~~ can be used to reduce the growth of an ovarian tumor, comprising the steps of:

- a) obtaining a sample of ovarian tumor cells;
- b) determining whether the ovarian tumor cells express one or more sensitivity markers identified in Tables 1-6; and
- c) identifying that paclitaxel and cisplatin ~~the agent~~ can be used to reduce the growth of the ovarian tumor cells when the one or more sensitivity markers are expressed.

2-4. **(Cancelled)**

5. **(Currently Amended)** The method of claim 70, wherein expression is determined by detecting the amount of an mRNA molecule comprising the corresponding RNA sequence of the polynucleotide sequence of SEQ ID NO:16 mRNA present in the sample.

6. **(Cancelled)**

7. **(Previously Presented)** The method of claim 1, wherein said ovarian tumor cells are obtained from an ovarian tumor cell line or an ovarian tumor obtained from a subject.

8. **(Currently Amended)** A method for determining whether ~~an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs~~ paclitaxel and ~~cisplatin derivatives~~ cannot be used to reduce the growth of an ovarian tumor, comprising the steps of:

- a) obtaining a sample of ovarian tumor cells;

- b) determining whether the ovarian tumor cells express one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1-6; and
- c) identifying that paclitaxel and cisplatin ~~the agent~~ cannot be used to reduce the growth of the ovarian tumor when one or more of the sensitivity markers in Tables 1-6 is not expressed ~~or is underexpressed~~ by the ovarian tumor cells.

9-11. **(Cancelled)**

12. **(Currently Amended)** The method of claim 71, wherein expression is determined by detecting the amount of an mRNA molecule comprising the corresponding RNA sequence of the polynucleotide sequence of SEQ ID NO:16 ~~mRNA~~ present in the sample.

13. **(Cancelled)**

14. **(Previously Presented)** The method of claim 8, wherein said ovarian tumor cells are obtained from an ovarian tumor cell line or an ovarian tumor obtained from a subject.

15-69. **(Cancelled)**

70. **(Previously Presented)** The method of claim 1, wherein the sensitivity marker is the marker of SEQ ID NO:16.

71. **(Previously Presented)** The method of claim 8, wherein the sensitivity marker is the marker of SEQ ID NO:16.